Michael Stocum

Michael Stocum is an entrepreneurial executive leader with two-plus decades of experience driving innovation (idea-to-product) and delivering transformational products that improve the lives of patients along with providing returns for investors. During his career, he has been a member/leader of multiple teams within life sciences companies bringing numerous pharmaceutical, biotech and molecular testing products to market. From his NC State University roots, including undergraduate and graduate research and early days as a scientist in industry, he steadily moved from the bench to the market and eventually the Board room. Throughout his career in both large companies such as GlaxoSmithKline and Organon Teknika (now part of Merck and bioMerieux) to emerging biotechs (including Inivata and Bantam Pharma), he has held global roles where he has provided strategic and operational leadership spanning the patient care value chain, from translational and clinical science to product development and commercial strategy to external partnership building, corporate fundraising and culture management. He carries a deep passion for improving patient care, enhancing wellness and advancing science for the benefit of humankind. Michael has contributed to the development of numerous drugs in clinical research and several approved cancer therapeutics including Tykerb and Votrient, as well as Abacavir for HIV. His ground-breaking work in building molecular testing products and companies has guided the use of dozens of therapeutics in cancer, infectious diseases, metabolic diseases, transplantation and hematology. Michael received his BS degrees from NCSU in Microbiology and Biochemistry, with a MS in Biotech Management. He is the founder of Personalized Medicine Partners and Opsepio Therapeutics, as well as the founding CEO of Inivata.